ライフサイエンスコーパス: febuxostat

1 s Review, we focus on the clinical trials of febuxostat.

2 proved urate-lowering drugs, allopurinol and febuxostat.

3 , 76% taking 80 mg, and 94% taking 120 mg of febuxostat.

4 rhea and dizziness were more frequent in the febuxostat 240 mg group.

5 lar frequency in the placebo (37%) and 40-mg febuxostat (35%) groups and with increased frequency in

6 Subjects received febuxostat (40 mg, 80 mg, 120 mg) or placebo once daily

7 in 53 percent of patients receiving 80 mg of febuxostat, 62 percent of those receiving 120 mg of febu

8 s: 64 percent of patients receiving 80 mg of febuxostat, 70 percent of those receiving 120 mg of febu

9 ts with impaired renal function treated with febuxostat 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11),

10 higher percentages of subjects treated with febuxostat 80 mg (48%), 120 mg (65%), and 240 mg (69%) a

11 r (480 micromol per liter) to receive either febuxostat (80 mg or 120 mg) or allopurinol (300 mg) onc

12 nction were randomized to receive once-daily febuxostat (80 mg, 120 mg, or 240 mg), allopurinol (300

13 The approval of febuxostat, a non-purine-analogue inhibitor of xanthine

14 er therapeutic agents in development include febuxostat, a nonpurine analogue xanthine oxidase inhibi

15 udy was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xanthine

16 Febuxostat, a novel nonpurine selective inhibitor of xan

17 Febuxostat, a novel xanthine oxidase inhibitor, represen

18 lopurinol-febuxostat sequential therapy; and febuxostat-allopurinol sequential therapy.

19 as 83 percent in patients receiving 80 mg of febuxostat and 66 percent in those receiving 120 mg of f

20 t-related adverse events were similar in the febuxostat and placebo groups.

21 tat, 62 percent of those receiving 120 mg of febuxostat, and 21 percent of those receiving allopurino

22 tat, 70 percent of those receiving 120 mg of febuxostat, and 64 percent of those receiving allopurino

23 A new xanthine oxidase inhibitor, febuxostat, and pegylated uricases are in clinical trial

24 and 66 percent in those receiving 120 mg of febuxostat, as compared with 50 percent in those receivi

25 Febuxostat, at a daily dose of 80 mg or 120 mg, was more

26 rios were investigated: fixed dose (80 mg of febuxostat daily, 0.80 success rate; 300 mg of allopurin

27 cess rate) and dose escalation (</=120 mg of febuxostat daily, 0.82 success rate; </=800 mg of allopu

28 ions at baseline and after PUA lowering with febuxostat (FBX) for 8 weeks.

29 allopurinol group (P=0.003) or the low-dose febuxostat group discontinued the study.

30 More patients in the high-dose febuxostat group than in the allopurinol group (P=0.003)

31 opurinol (P<0.001 for the comparison of each febuxostat group with the allopurinol group).

32 Four of the 507 patients in the two febuxostat groups (0.8 percent) and none of the 253 pati

33 ith increased frequency in the higher dosage febuxostat groups (43% taking 80 mg; 55% taking 120 mg).

34 0.31 for the comparison between the combined febuxostat groups and the allopurinol group).

35 -mg, 44% in the 80-mg, and 59% in the 120-mg febuxostat groups.

36 Patients for whom allopurinol or febuxostat is a suitable initial urate-lowering treatmen

37 herapies such as urate synthesis inhibitors (febuxostat is already FDA approved and BCX4208 is in dev

38 Studies of allopurinol and febuxostat lowering of serum urate have once again raise

39 Finally, a potent UA synthesis inhibitor, febuxostat, mitigated asthma phenotypes that were caused

40 At all doses studied, febuxostat more effectively lowered and maintained serum

41 ere evaluated: no treatment; allopurinol- or febuxostat-only therapy; allopurinol-febuxostat sequenti

42 that urate-lowering therapy (allopurinol or febuxostat) reduces long-term risk for acute gout attack

43 Treatment with febuxostat resulted in a significant reduction of sUA le

44 Dose-escalation allopurinol-febuxostat sequential therapy is cost-effective compared

45 s ratios of dose escalation with allopurinol-febuxostat sequential therapy remained lower than the wi

46 Dose-escalation allopurinol-febuxostat sequential therapy was more costly but more e

47 nol- or febuxostat-only therapy; allopurinol-febuxostat sequential therapy; and febuxostat-allopurino

48 r gout flares, which were more frequent with febuxostat than with allopurinol.

49 Febuxostat therapy was safe and well tolerated.

50 Greater proportions of febuxostat-treated patients than placebo-treated patient

51 Nevertheless, both allopurinol and febuxostat treatment has sustained the hypothesis that h

52 xostat vs. allopurinol; P=0.23 for 120 mg of febuxostat vs. allopurinol).

53 xostat vs. allopurinol; P=0.16 for 120 mg of febuxostat vs. allopurinol).

54 e receiving allopurinol (P=0.08 for 80 mg of febuxostat vs. allopurinol; P=0.16 for 120 mg of febuxos

55 e receiving allopurinol (P=0.99 for 80 mg of febuxostat vs. allopurinol; P=0.23 for 120 mg of febuxos